| dc.contributor.advisor | 吳文傑 | zh_TW |
| dc.contributor.advisor | Wu, Jack | en_US |
| dc.contributor.author (Authors) | 林芮珊 | zh_TW |
| dc.contributor.author (Authors) | Lin, Sandy | en_US |
| dc.creator (作者) | 林芮珊 | zh_TW |
| dc.creator (作者) | Lin, Sandy | en_US |
| dc.date (日期) | 2008 | en_US |
| dc.date.accessioned | 14-Sep-2009 09:50:21 (UTC+8) | - |
| dc.date.available | 14-Sep-2009 09:50:21 (UTC+8) | - |
| dc.date.issued (上傳時間) | 14-Sep-2009 09:50:21 (UTC+8) | - |
| dc.identifier (Other Identifiers) | G0095933022 | en_US |
| dc.identifier.uri (URI) | https://nccur.lib.nccu.edu.tw/handle/140.119/31347 | - |
| dc.description (描述) | 碩士 | zh_TW |
| dc.description (描述) | 國立政治大學 | zh_TW |
| dc.description (描述) | 國際經營管理碩士班(IMBA) | zh_TW |
| dc.description (描述) | 95933022 | zh_TW |
| dc.description (描述) | 97 | zh_TW |
| dc.description.abstract (摘要) | 研究全球藥界併購趨勢及其影響力：以拜耳先靈西藥部為例 | zh_TW |
| dc.description.abstract (摘要) | Abstract A Study of M&A Trends and Effects on Global Pharmaceutical Industry: Using Bayer Schering Pharma as a Model By Sandy, Jui-San Lin The driving force for me to conduct a case writing related to M&A trends and effects in pharmaceutical industry as my master thesis is because I have been working with a global pharmaceutical subsidiary in Taipei whereby the company had experienced a series of post merger integrations. I was surprised by my research as 3 out of the 9 largest worldwide M&A transactions in 2000s were associated with pharmaceutics. The data is even more shocking as the total M&A value in pharmaceutical industry had contributed to almost 14% of the top transactions from 1990s to present (Table 1.2 & 1.3). I hope by going through the process, I will be able to learn more about the industry as what are the underlying factors and key considerations behind these mergers, how do those consolidated companies benefit from the action and where is the future? In my dissertation, I will first define what M&A action is as in general; present an overview on the global pharmaceutical world as what are the recent developments of M&A activities. Then I will concentrate on Bayer Healthcare and study its integration process with German Schering. | en_US |
| dc.description.abstract (摘要) | 1 Introduction………………………………………….…………..….1 1.1 Defining M&A……………………………….…………..……1 1.2 Synergies…..………………………………….………..……...3 1.3 The Big Waves in M&A...…………………….………..……..4 2 History of Pharma Industry.…………………………………….…12 3 Market Analysis on Pharma Business.………………………….…16 3.1 PEST(Political, Economic, Social and Technological)………16 3.2 Porter Five Forces……………………………………………19 4 Direction in Pharmaceutics Merges.…………………………….…22 4.1 Vertical Waves in 1990s...…………………………………….22 4.2 Horizontal Waves from Early 2000s………………………….25 Case I Pfizer…………………………………………………..26 Case II GSK…………………………………………………..30 5 Background of the Main Case.……….………………………….…35 5.1 History of Bayer...…………………………………………….35 5.2 History of Schering AG……………………………………….40 6 “The merge” for two becoming one….………………………….…42 6.1 The forming of Bayer Schering Pharma…….………………..45 6.2 Local Integration…………………………….………………..48 7 Conclusion …………………………………………………………57 References …………………………………………………………......59 | - |
| dc.description.tableofcontents | 1 Introduction………………………………………….…………..….1 1.1 Defining M&A……………………………….…………..……1 1.2 Synergies…..………………………………….………..……...3 1.3 The Big Waves in M&A...…………………….………..……..4 2 History of Pharma Industry.…………………………………….…12 3 Market Analysis on Pharma Business.………………………….…16 3.1 PEST(Political, Economic, Social and Technological)………16 3.2 Porter Five Forces……………………………………………19 4 Direction in Pharmaceutics Merges.…………………………….…22 4.1 Vertical Waves in 1990s...…………………………………….22 4.2 Horizontal Waves from Early 2000s………………………….25 Case I Pfizer…………………………………………………..26 Case II GSK…………………………………………………..30 5 Background of the Main Case.……….………………………….…35 5.1 History of Bayer...…………………………………………….35 5.2 History of Schering AG……………………………………….40 6 “The merge” for two becoming one….………………………….…42 6.1 The forming of Bayer Schering Pharma…….………………..45 6.2 Local Integration…………………………….………………..48 7 Conclusion …………………………………………………………57 References …………………………………………………………......59 | zh_TW |
| dc.language.iso | en_US | - |
| dc.source.uri (資料來源) | http://thesis.lib.nccu.edu.tw/record/#G0095933022 | en_US |
| dc.subject (關鍵詞) | 併購 | zh_TW |
| dc.title (題名) | 研究全球藥界併購趨勢及其影響力：以拜耳先靈西藥部為例 | zh_TW |
| dc.title (題名) | A study of M&A trends and effects on global pharmaceutical industry: using bayer schering pharma as a model | en_US |
| dc.type (資料類型) | thesis | en |
| dc.relation.reference (參考文獻) | 1. Patrick A. Gaughan, Mergers (2002), Acquisitions and Corporate Restructuring 3rd Edition: Wiley M&A Library, p.23-55 | zh_TW |
| dc.relation.reference (參考文獻) | 2. Jemison, D. B. & Sitkin, S.B. (1986), Corporate Acquisitions, A process perspective: Academy of Management Review, 11, p.145-163 | zh_TW |
| dc.relation.reference (參考文獻) | 3. Judelson, D. N. (1969) The Conglomerate – Corporate Form of the Future: Harvard Business Review p.8-12 | zh_TW |
| dc.relation.reference (參考文獻) | 4. Harold Geneen (1984), Managing: Doubleday | zh_TW |
| dc.relation.reference (參考文獻) | 5. Goold, M., & Quinn, J. B. (1990) Strategic Control: Hutchinson & Economist Publication | zh_TW |
| dc.relation.reference (參考文獻) | 6. Jensen, M. C. (1989), The Eclipse of Public Corporation: Harvard Business Review p.61-74 | zh_TW |
| dc.relation.reference (參考文獻) | 7. Goold, M., & Luchs, K. (1993) Why Diversify? Four Decades of Management Thinking: Academy of Management Thinking 7(3), p.7-25 | zh_TW |
| dc.relation.reference (參考文獻) | 8. Sikora, M. (1995), The Winding Trail: A 30 Years M&A Profile Dynamism: Mergers & Acquisitions p.45-50 | zh_TW |
| dc.relation.reference (參考文獻) | 9. Shleifer, A., & Vishny R. W. (1994), Takeovers in the 1960s & 1980s: Evidence & Implications: Harvard Business School Press | zh_TW |
| dc.relation.reference (參考文獻) | 10. Sikora, M. (1997), Why the M&A Boom Isn’t Dying Down: Mergers & Acquisitions p.5-7 | zh_TW |
| dc.relation.reference (參考文獻) | 11. Watson, R. Jr. (2000), What to Do Merge, Diversify What to Do Expand and Liquidate: The Cornell Hotel & Administration Quarterly, 1: p.14-21 | zh_TW |
| dc.relation.reference (參考文獻) | 12. Institute of Mergers, Acquisitions and Alliances (MANDA): http://www.imaa-institute.org/en/index.php | zh_TW |
| dc.relation.reference (參考文獻) | 13. Med Ad News: http://www.pharmalive.com/magazines/medad/?date=09%2F2007 | zh_TW |
| dc.relation.reference (參考文獻) | 14. PBM Highlights: http://www.okcu.edu/economics/ASSIGN/JWILLNER/5203/Articles/DrugsCompaniesMergerDeMerger.pdf | zh_TW |
| dc.relation.reference (參考文獻) | 15. Oligopoly Watch: http://www.badfaithinsurance.org/reference/GMCOPBM/0011a.htm | zh_TW |
| dc.relation.reference (參考文獻) | 16. http:www.contractpharma.com | zh_TW |
| dc.relation.reference (參考文獻) | 17. Stephen P. Bradley, Matthew Sandoval (2000), The Drug Wars: Pfizer’s Hostile Bid for Warner-Lamber in 1999: Harvard Business Review | zh_TW |
| dc.relation.reference (參考文獻) | 18. Pfizer Website: http://www.pfizer.com/home/ | zh_TW |
| dc.relation.reference (參考文獻) | 19. GSK Website: http://www.gsk.com | zh_TW |
| dc.relation.reference (參考文獻) | 20. Bayer Website: http://www.bayer.com | zh_TW |
| dc.relation.reference (參考文獻) | 21. Bayer Schering Pharma Website: http://www.bayerscheringpharma.de/scripts/pages/de/index.php | zh_TW |
| dc.relation.reference (參考文獻) | 22. http://www.investopedia.com/university/mergers/mergers1.asp | zh_TW |
| dc.relation.reference (參考文獻) | 23. http://www.wikipedia.com | zh_TW |
| dc.relation.reference (參考文獻) | 24. http://www.answers.com | zh_TW |
